Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Charles C. Wykoff, MD PhD"'
Autor:
Dilraj S. Grewal, MD, Charles C. Wykoff, MD PhD, Divya D’Souza, MD, Valentine Jehl, MSc, Iulian Alecu, MD, Glenn J. Jaffe, MD
Publikováno v:
Ophthalmology Science, Vol 4, Iss 1, Pp 100361- (2024)
Purpose: The aim of this analysis was to characterize the spectrum of inflammatory changes arising from brolucizumab use in routine clinical practice. Design: Retrospective analysis of fluorescein angiography (FA), fundus photography (FP) and OCT ima
Externí odkaz:
https://doaj.org/article/2f7601f3cd794369a952372055c07c88
Autor:
Sudeshna Sil Kar, PhD, Joseph Abraham, MD, Charles C. Wykoff, MD, PhD, Duriye Damla Sevgi, MD, Leina Lunasco, BS, David M. Brown, MD, Sunil K. Srivastava, MD, Anant Madabhushi, PhD, Justis P. Ehlers, MD
Publikováno v:
Ophthalmology Science, Vol 2, Iss 2, Pp 100123- (2022)
Purpose: Various pathways and cytokines are implicated in pathogenesis of diabetic macular edema (DME). Computational imaging biomarkers (CIBs) of vessel tortuosity from ultra-widefield fluorescein angiography (UWFA) and texture patterns from OCT ima
Externí odkaz:
https://doaj.org/article/b1f9b7e001b1400987697cf9fe886866
Autor:
Nicole Eter, MD, PhD, Rishi P. Singh, MD, Francis Abreu, PhD, Kemal Asik, PhD, Karen Basu, PhD, Caroline Baumal, MD, Andrew Chang, PhD, Karl G. Csaky, MD, Zdenka Haskova, MD, PhD, Hugh Lin, MD, Carlos Quezada Ruiz, MD, Paisan Ruamviboonsuk, MD, David Silverman, MSc, MRCOphth, Charles C. Wykoff, MD, PhD, Jeffrey R. Willis, MD, PhD
Publikováno v:
Ophthalmology Science, Vol 2, Iss 1, Pp 100111- (2022)
Purpose: Faricimab is a novel anti–angiopoietin-2 and anti–vascular endothelial growth factor (VEGF) bispecific antibody with high affinities and specificities for both VEGF and angiopoietin-2. It is postulated that targeting angiogenic factors a
Externí odkaz:
https://doaj.org/article/709fe9164f104f6b90d25b01ec8888bb
Autor:
M. Elizabeth Hartnett, MD, Ward Fickweiler, MD, PhD, Anthony P. Adamis, MD, Michael Brownlee, MD, Arup Das, MD, PhD, Elia J. Duh, MD, Edward P. Feener, PhD, George King, MD, Renu Kowluru, PhD, Ulrich F.O. Luhmann, PhD, Federica Storti, PhD, Charles C. Wykoff, MD, PhD, Lloyd Paul Aiello, MD, PhD
Publikováno v:
Ophthalmology Science, Vol 4, Iss 5, Pp 100521- (2024)
Purpose: Hyperglycemia is a major risk factor for early lesions of diabetic retinal disease (DRD). Updating the DRD staging system to incorporate relevant basic and cellular mechanisms pertinent to DRD is necessary to better address early disease, di
Externí odkaz:
https://doaj.org/article/d168a05b499a4366a82cce9f5b9f8421
Autor:
Mark R. Barakat, MD, David Brown, MD, Allen Hu, MD, Rahul N. Khurana, MD, Dennis Marcus, MD, Joel Pearlman, MD, PhD, Charles C. Wykoff, MD, PhD, Barry Kapik, MS, Thomas Ciulla, MD, MBA
Publikováno v:
Ophthalmology Science, Vol 5, Iss 1, Pp 100586- (2025)
Purpose: To evaluate the safety and tolerability of a single dose of axitinib injectable suspension (CLS-AX), a pan-anti-VEGF tyrosine kinase inhibitor (TKI), administered via suprachoroidal injection in patients with neovascular age-related macular
Externí odkaz:
https://doaj.org/article/ff6174f6c3444b01bcdabdb6dcbdd020
Autor:
Charles C. Wykoff, MD, PhD, Vincent Garmo, MHS, David Tabano, PhD, Alicia Menezes, MD, Eunice Kim, RPh, MS, Helene B. Fevrier, MSm, Andrew LaPrise, BS, Theodore Leng, MD, MS
Publikováno v:
Ophthalmology Science, Vol 4, Iss 2, Pp 100421- (2024)
Purpose: To evaluate anti-VEGF treatment patterns and the influence of patient demographic and clinical characteristics on up to 6-year vision outcomes in neovascular age-related macular degeneration. Design: Retrospective, multicenter, noninterventi
Externí odkaz:
https://doaj.org/article/c66cb484fc3f41e4a478a6c820de567e
Autor:
Mirataollah Salabati, MD, Charles Huang, BS, Alireza Kamalipour, MD, Hannah J. Yu, BS, Raziyeh Mahmoudzadeh, MD, Karen Jeng-Miller, MD, MPH, Eric Chen, MD, Chirag P. Shah, MD, MPH, Charles C. Wykoff, MD, PhD, Jason Hsu, MD
Publikováno v:
Ophthalmology Science, Vol 4, Iss 2, Pp 100372- (2024)
Purpose: To compare visual acuity (VA) changes using standardized ETDRS best-corrected visual acuity (BCVA) and nonstandardized Snellen VA among subjects enrolled in clinical trials. Design: Retrospective study. Participants: Patients enrolled in pro
Externí odkaz:
https://doaj.org/article/9798ad4bb51f44c3bfb75be70009f8ec
Autor:
Lars-Olof Hattenbach, MD, PhD, Francis Abreu, PhD, Pablo Arrisi, PhD, Karen Basu, PhD, Carl J. Danzig, MD, Robyn Guymer, MD, PhD, Zdenka Haskova, MD, PhD, Jeffrey S. Heier, MD, Aachal Kotecha, PhD, Ying Liu, PhD, Anat Loewenstein, MD, András Seres, MD, Jeffrey R. Willis, MD, PhD, Charles C. Wykoff, MD, PhD, Liliana P. Paris, MD, PhD
Publikováno v:
Ophthalmology Science, Vol 3, Iss 3, Pp 100302- (2023)
Purpose: Dual inhibition of angiopoietin-2 and VEGF-A with faricimab (Vabysmo) offers excellent visual acuity gains with strong durability in patients with diabetic macular edema (ME) and neovascular age-related macular degeneration. The phase III BA
Externí odkaz:
https://doaj.org/article/868cf61b8f6b4378aa110bd7320825d8